MITI minimum information guidelines for highly multiplexed tissue images

doi:10.1038/s41592-022-01415-4

MITI minimum information guidelines for highly multiplexed tissue images

Research output: Contribution to journal › Comment/debate

Original language	American English
Pages (from-to)	262-267
Number of pages	6
Journal	Nature Methods
Volume	19
Issue number	3
DOIs	https://doi.org/10.1038/s41592-022-01415-4
State	Published - 1 Mar 2022
Externally published	Yes

All Science Journal Classification (ASJC) codes

Biotechnology
Biochemistry
Molecular Biology
Cell Biology

Access to Document

10.1038/s41592-022-01415-4

Cite this

@article{744860d86784456e8cad0caf9f981832,

title = "MITI minimum information guidelines for highly multiplexed tissue images",

author = "Denis Schapiro and Clarence Yapp and Artem Sokolov and Reynolds, \{Sheila M.\} and Chen, \{Yu An\} and Damir Sudar and Yubin Xie and Jeremy Muhlich and Raquel Arias-Camison and Sarah Arena and Taylor, \{Adam J.\} and Milen Nikolov and Madison Tyler and Lin, \{Jia Ren\} and Burlingame, \{Erik A.\} and Abravanel, \{Daniel L.\} and Samuel Achilefu and Ademuyiwa, \{Foluso O.\} and Adey, \{Andrew C.\} and Rebecca Aft and Ahn, \{Khung Jun\} and Fatemeh Alikarami and Shahar Alon and Orr Ashenberg and Ethan Baker and Baker, \{Gregory J.\} and Shovik Bandyopadhyay and Peter Bayguinov and Jennifer Beane and Winston Becker and Kathrin Bernt and Betts, \{Courtney B.\} and Julie Bletz and Tim Blosser and Adrienne Boire and Boland, \{Genevieve M.\} and Boyden, \{Edward S.\} and Elmar Bucher and Raphael Bueno and Qiuyin Cai and Francesco Cambuli and Joshua Campbell and Song Cao and Wagma Caravan and Ronan Chalign{\'e} and Chan, \{Joseph M.\} and Sara Chasnoff and Deyali Chatterjee and Chen, \{Alyce A.\} and Ofir Cohen",

note = "Funding Information: This work is supported by the HTAN Consortium and the Cancer Systems Biology Consortium (CSBC). A list of all current HTAN Consortium members can be found at https://humantumoratlas.org/ . This work was supported by the following grants from the US National Cancer Institute under the Human Tumor Atlas Network (HTAN): U2C CA233262 (Harvard Medical School), U2C CA233280 (OHSU), U2C CA233195 (Boston DFCI Broad), U2C CA233291 (Vanderbilt University Medical Center), U2C CA233311 (Stanford University), U2C CA233238 (Boston University Medical Campus), U2C CA233285 (Children{\textquoteright}s Hospital of Philadelphia), U2C CA233303 (Washington University St. Louis), U2C CA233280 (Oregon Health and Science University), U2C CA233284 (Memorial Sloan Kettering Cancer Center) and U2C CA233254 (Duke University Medical Center), and by other public support including U54 CA225088 (S.S., P.K.S.) and U24 CA233243 (Dana-Farber Cancer Institute, Emory University, Institute for Systems Biology, Memorial Sloan Kettering Cancer Center, Sage Bionetworks). D. Schapiro was funded by an Early Postdoc Mobility fellowship (no. P2ZHP3\_181475) from the Swiss National Science Foundation and was a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRQ-03-20); D. Schapiro is currently supported by the BMBF (01ZZ2004). N.G. was funded by the US National Institutes of Health Human BioMolecular Atlas Program (HuBMAP) OT2 OD026677 and M.D.H. by NCI/NIH Task Order No. HHSN26110071 under Contract No. HHSN2612015000031. Funding Information: P.K.S. is a member of the Scientific Advisory Board (SAB) or Board of Directors of Applied Biomath, RareCyte Inc. and Glencoe Software, which distributes a commercial version of the OMERO data management platform; P.K.S. is also a member of the NanoString SAB and a consultant to Merck and Montai Health. In the past five years, the Sorger laboratory has received research funding from Novartis and Merck. P.K.S. declares that none of these relationships have influenced the content of this manuscript. S.S. is a consultant for RareCyte Inc. N.G. is a co-founder and equity owner of Datavisyn. D. Schapiro is a consultant for Roche Glycart AG. J.R.S. is founder and CEO of Glencoe Software, which distributes a commercial version of the OMERO data management platform. S.J.R. receives research funding from Bristol Myers Squibb, Merck, Affimed and Kite/Gilead and is on the SAB of Immunitas Therapeutics. D. Sudar is employed by Quantitative Imaging Systems LLC. E.A.B. is an employee of Indica Labs.",

year = "2022",

month = mar,

day = "1",

doi = "10.1038/s41592-022-01415-4",

language = "American English",

volume = "19",

pages = "262--267",

journal = "Nature Methods",

issn = "1548-7091",

publisher = "Nature Research",

number = "3",

}

TY - JOUR

T1 - MITI minimum information guidelines for highly multiplexed tissue images

AU - Schapiro, Denis

AU - Yapp, Clarence

AU - Sokolov, Artem

AU - Reynolds, Sheila M.

AU - Chen, Yu An

AU - Sudar, Damir

AU - Xie, Yubin

AU - Muhlich, Jeremy

AU - Arias-Camison, Raquel

AU - Arena, Sarah

AU - Taylor, Adam J.

AU - Nikolov, Milen

AU - Tyler, Madison

AU - Lin, Jia Ren

AU - Burlingame, Erik A.

AU - Abravanel, Daniel L.

AU - Achilefu, Samuel

AU - Ademuyiwa, Foluso O.

AU - Adey, Andrew C.

AU - Aft, Rebecca

AU - Ahn, Khung Jun

AU - Alikarami, Fatemeh

AU - Alon, Shahar

AU - Ashenberg, Orr

AU - Baker, Ethan

AU - Baker, Gregory J.

AU - Bandyopadhyay, Shovik

AU - Bayguinov, Peter

AU - Beane, Jennifer

AU - Becker, Winston

AU - Bernt, Kathrin

AU - Betts, Courtney B.

AU - Bletz, Julie

AU - Blosser, Tim

AU - Boire, Adrienne

AU - Boland, Genevieve M.

AU - Boyden, Edward S.

AU - Bucher, Elmar

AU - Bueno, Raphael

AU - Cai, Qiuyin

AU - Cambuli, Francesco

AU - Campbell, Joshua

AU - Cao, Song

AU - Caravan, Wagma

AU - Chaligné, Ronan

AU - Chan, Joseph M.

AU - Chasnoff, Sara

AU - Chatterjee, Deyali

AU - Chen, Alyce A.

AU - Cohen, Ofir

N1 - Funding Information: This work is supported by the HTAN Consortium and the Cancer Systems Biology Consortium (CSBC). A list of all current HTAN Consortium members can be found at https://humantumoratlas.org/ . This work was supported by the following grants from the US National Cancer Institute under the Human Tumor Atlas Network (HTAN): U2C CA233262 (Harvard Medical School), U2C CA233280 (OHSU), U2C CA233195 (Boston DFCI Broad), U2C CA233291 (Vanderbilt University Medical Center), U2C CA233311 (Stanford University), U2C CA233238 (Boston University Medical Campus), U2C CA233285 (Children’s Hospital of Philadelphia), U2C CA233303 (Washington University St. Louis), U2C CA233280 (Oregon Health and Science University), U2C CA233284 (Memorial Sloan Kettering Cancer Center) and U2C CA233254 (Duke University Medical Center), and by other public support including U54 CA225088 (S.S., P.K.S.) and U24 CA233243 (Dana-Farber Cancer Institute, Emory University, Institute for Systems Biology, Memorial Sloan Kettering Cancer Center, Sage Bionetworks). D. Schapiro was funded by an Early Postdoc Mobility fellowship (no. P2ZHP3_181475) from the Swiss National Science Foundation and was a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRQ-03-20); D. Schapiro is currently supported by the BMBF (01ZZ2004). N.G. was funded by the US National Institutes of Health Human BioMolecular Atlas Program (HuBMAP) OT2 OD026677 and M.D.H. by NCI/NIH Task Order No. HHSN26110071 under Contract No. HHSN2612015000031. Funding Information: P.K.S. is a member of the Scientific Advisory Board (SAB) or Board of Directors of Applied Biomath, RareCyte Inc. and Glencoe Software, which distributes a commercial version of the OMERO data management platform; P.K.S. is also a member of the NanoString SAB and a consultant to Merck and Montai Health. In the past five years, the Sorger laboratory has received research funding from Novartis and Merck. P.K.S. declares that none of these relationships have influenced the content of this manuscript. S.S. is a consultant for RareCyte Inc. N.G. is a co-founder and equity owner of Datavisyn. D. Schapiro is a consultant for Roche Glycart AG. J.R.S. is founder and CEO of Glencoe Software, which distributes a commercial version of the OMERO data management platform. S.J.R. receives research funding from Bristol Myers Squibb, Merck, Affimed and Kite/Gilead and is on the SAB of Immunitas Therapeutics. D. Sudar is employed by Quantitative Imaging Systems LLC. E.A.B. is an employee of Indica Labs.

PY - 2022/3/1

Y1 - 2022/3/1

UR - http://www.scopus.com/inward/record.url?scp=85126388877&partnerID=8YFLogxK

U2 - 10.1038/s41592-022-01415-4

DO - 10.1038/s41592-022-01415-4

M3 - Comment/debate

C2 - 35277708

SN - 1548-7091

VL - 19

SP - 262

EP - 267

JO - Nature Methods

JF - Nature Methods

IS - 3

ER -

MITI minimum information guidelines for highly multiplexed tissue images

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this